ABL Bio (XKRX:298380) Receivables Turnover : 0.00 (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is ABL Bio Receivables Turnover?

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. ABL Bio's Revenue for the three months ended in Mar. 2024 was ₩7,937 Mil. ABL Bio's average Accounts Receivable for the three months ended in Mar. 2024 was ₩0 Mil.

ABL Bio Receivables Turnover Historical Data

The historical data trend for ABL Bio's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ABL Bio Receivables Turnover Chart

ABL Bio Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Receivables Turnover

Get a 7-Day Free Trial

0.75

18.62

12.25

ABL Bio Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Receivables Turnover	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of ABL Bio's Receivables Turnover

For the Biotechnology subindustry, ABL Bio's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ABL Bio's Receivables Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ABL Bio's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where ABL Bio's Receivables Turnover falls into.

ABL Bio Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

ABL Bio's Receivables Turnover for the fiscal year that ended in Dec. 2023 is calculated as

	Receivables Turnover (A: Dec. 2023 )
=	Revenue	/	Average Total Inventories
=	Revenue (A: Dec. 2023 )	/ (	(Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )
=	65547.055	/ (	(0	+	0)	/	1 )
=	65547.055	/	0
=	N/A

ABL Bio's Receivables Turnover for the quarter that ended in Mar. 2024 is calculated as

	Receivables Turnover (Q: Mar. 2024 )
=	Revenue	/	Average Total Inventories
=	Revenue (Q: Mar. 2024 )	/ (	(Accounts Receivable (Q: Dec. 2023 )	+	Accounts Receivable (Q: Mar. 2024 ))	/	count )
=	7937.206	/ (	(0	+	0)	/	1 )
=	7937.206	/	0
=	N/A

ABL Bio (XKRX:298380) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

ABL Bio Receivables Turnover Related Terms

Thank you for viewing the detailed overview of ABL Bio's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

ABL Bio (XKRX:298380) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ABL Bio Inc (XKRX:298380) » Definitions » Receivables Turnover

Comparable Companies

Traded in Other Exchanges

N/A

Address

2nd Floor, 16 Daewangpangyo-Ro 712, Beon-Gil, Bundang-Gu, Gyeonggi-do, Seongnam-si, KOR, 13488

Website

https://www.ablbio.com

ABL Bio Inc is a Korean biotech research company. The company is engaged in the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. Its pipeline products include ABL001 an Bispecific Antibody, ABL201-205 an Antibody Drug Conjugate, T cell engager, Dual Immune Cell Targeting BsAb an Immuno-Oncology, ABL301 an BBB-Penetrating Bispecific Antibody.

ABL Bio (XKRX:298380) Headlines

No Headlines